News

Survey on new KIC on water, marine and maritime sectors and ecosystems (WMM)

Published on | 11 months ago

Programmes Agro-Food, Environment EIE EIT Missions

The Norwegian Unicerity of Science and Technology (NTNU) has been tasked by the STOA of the European Parliament to coordinate a study leading to the preparation of a report aiming to provide input on how a KIC in the water, marine and maritime sectors and ecosystems can contribute substantially to secure sustainable innovation, value creation and quality of life for European citizens.

The study is currently led by a team of experts which have also elaborated a survey to collect input from EU stakeholders out of which to elaborate the report outcomes to be presented to the STOA this April 2024.

The survey on sustainable innovation in the fields of water, marine and marine sectors can be accessed by clicking on the active link.

The survey will take approximately 10-15 minutes, depending on how detailed your responses are, and whether you choose to respond to all parts or not.

Deadline for your input is 26/02/2024 at 23:59h.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1523 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.